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Health aspects of ®sh and n-3 polyunsaturated fatty acids from
plant and marine origin.
EAM de Deckere1, O Korver1, PM Verschuren1 and MB Katan2
1Unilever Nutrition Centre, Unilever Research Vlaardingen, Vlaardingen, The Netherlands; and 2Department of Human Nutrition and
Epidemiology, Wageningen Agricultural University, Wageningen, The Netherlands
An expert workshop reviewed the health effects of n-3 polyunsaturated fatty acids (PUFA), and came to the
following conclusions.
1. Consumption of ®sh may reduce the risk of coronary heart disease (CHD). People at risk for CHD are
therefore advised to eat ®sh once a week. The n-3 PUFA in ®sh are probably the active agents. People who do
not eat ®sh should consider obtaining 200 mg of very long chain n-3 PUFA daily from other sources.
2. Marine n-3 PUFA somewhat alleviate the symptoms of rheumatoid arthritis.
3. There is incomplete but growing evidence that consumption of the plant n-3 PUFA, alpha-linolenic acid,
reduces the risk of CHD. An intake of 2 g/d or 1% of energy of alpha-linolenic acid appears prudent.
4. The ratio of total n-3 over n-6 PUFA (linoleic acid) is not useful for characterising foods or diets because
plant and marine n-3 PUFA show different effects, and because a decrease in n-6 PUFA intake does not
produce the same effects as an increase in n-3 PUFA intake. Separate recommendations for alpha-linolenic
acid, marine n-3 PUFA and linoleic acid are preferred.
Sponsorship: Supported by a grant from Unilever Research.
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Introduction
This paper summarises the conclusions of an expert work-
shop on the health aspects of ®sh and n-3 polyunsaturated
fatty acids (PUFA). The objectives of the workshop were
to formulate scienti®cally sound conclusions on the
health effects of (fatty) ®sh and the use of plant (alpha-
linolenic acid: C18:3 n-3) and marine n-3 PUFA, mainly
eicosapentaenoic acid (EPA, C20:5 n-3) and docosahexa-
enoic acid (DHA, C22:6 n-3) in products for health reasons.
The discussions were held on the basis of questions sent to
the participants beforehand, and on brief introductions by
participants. The discussions were held in four sessions:
®sh and health, health effects of plant and marine n-3
PUFA, human experiments with n-3 PUFA, and conclu-
sions and recommendations.
Fish and health
Does the consumption of ®sh prevent coronary heart
disease (CHD)? What is the optimal intake (amount and
frequency) of ®sh?
Several prospective observational studies and a randomised
factorial trial showed that one serving of ®sh weekly may
decrease the risk of fatal CHD by approximately 40%
relative to no ®sh (Burr et al, 1989; Ascherio et al, 1995;
Kromhout et al, 1995; Gillum et al, 1996; Daviglus et al,
1997). Higher intakes did not provide greater protection.
The prospective studies had a comparable methodology,
compared either ®sh with no ®sh or low doses of marine
n-3 PUFA (®sh oil) with no marine n-3 PUFA, and give a
consistent picture of a reduction in CHD for the ®sh and
marine n-3 PUFA groups. No inverse association between
®sh intake and fatal CHD has been found in a number of
other prospective studies. This was probably due to the
higher overall ®sh intakes (Lapidus et al, 1986; Morris et
al, 1995). These latter studies do not contradict the hypoth-
esis of bene®cial effects of one serving of ®sh per week.
They do strengthen, however, the conclusion that larger
amounts of ®sh are not associated with increased bene®ts.
Does fatty ®sh or the EPA/DHA content of the diet have a
speci®c role in the prevention of CHD?
Much of the ®sh consumed in the epidemiological studies
was probably lean white ®sh. Combining data on the
consumption of ®sh and the effects on CHD risk parameters
with insights on mechanisms make it plausible, but not
certain, that the very long chain n-3 PUFA were the ®sh
components which caused the decrease in the risk of fatal
CHD (Burr et al, 1989; Siscovick et al, 1995; Singh et al,
1997).
Does consumption of ®sh protect against cancer?
There is no proof that ®sh consumption decreases cancer
risk. In animal experiments high doses of marine n-3 PUFA
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inhibited the development of chemically-induced breast
and colorectal cancers in the promotion phase, but probably
not in the initiation phase. Epidemiological studies on ®sh
and marine n-3 PUFA and cancer show variable results, but
most studies show an inverse relationship between ®sh
intake and the risk of breast and colorectal cancer (Boutron
et al, 1991; Neuget et al, 1993; Sasaki et al, 1993). These
studies, however, provide little information on n-3 PUFA
intakes. Recent epidemiological studies suggest an inter-
action between animal fat and ®sh from which might be
hypothesised that marine n-3 PUFA protect against the
effect of animal fat in colorectal cancer (Caygill et al,
1996). In trials with patients prone to development of
colorectal adenomas marine n-3 PUFA have been found
to `normalise' hyperproliferation of mucosal crypt cells
(Anti et al, 1992).
Health effects of plant and marine n-3 PUFA
Does alpha-linolenic acid protect against CHD?
Epidemiological studies (Dolecek, 1992; Ascherio et al,
1996) and one clinical trial (De Lorgeril et al, 1994)
suggest that intake of alpha-linolenic acid-rich food can
decrease the risk of myocardial infarction and death. A
relative de®ciency of n-3 PUFA may be present in a large
proportion of the population and might be a factor in CHD.
In the Health Professional Follow-up Study the relative risk
of CHD for a one energy-% increase in alpha-linolenic acid
was 0.41 after adjustment for standard risk factors and
intake of ®bre and total fat (Ascherio et al, 1996). An
increase in arterial compliance by dietary alpha-linolenic
acid, which might decrease the work load of the heart,
might contribute to a reduced risk in CHD by alpha-
linolenic acid (Nestel et al, 1997). Arterial compliance is
also increased by marine n-3 PUFA in diabetics.
Can the bene®ts of EPA/DHA be obtained through alpha-
linolenic acid? If so, what is the conversion factor and on
which criteria should this be judged?
The effects of EPA/DHA can not be fully reproduced by
alpha-linolenic acid, even in high doses. Conversion of
alpha-linolenic acid into EPA might play a role in the
protection against CHD (Allman et al, 1995; Freese &
Mutanen, 1997). However, the ef®cacy of alpha-linolenic
acid in raising plasma EPA levels is low, alpha-linolenic
acid is mainly oxidised, whereas EPA is incorporated into
complex lipids. For every 10 g of dietary alpha-linolenic
acid 0.5 ± 1 g EPA has been found to be incorporated into
complex lipids (Emken et al, 1990; Valsta et al, 1996).
Supplementation with alpha-linolenic acid (10 g/d or more),
however, minimally affected cellular phospholipid DHA
levels (Mantzioris et al, 1994). The conversion ratio is a
crude measure of conversion plus incorporation and
depends on the dose of alpha-linolenic acid and the content
of other PUFA in the diet (mainly linoleic acid). Further
studies are required to obtain quantitative conclusions on
the effect of dietary alpha-linolenic acid on tissue contents
of EPA and DHA.
Is the conversion of alpha-linolenic acid to very long chain
PUFA in¯uenced by age or disease state?
There are very little quantitative data available on the
effects of age and disease on the conversion of alpha-
linolenic acid into very long chain PUFA (Bjerve et al,
1989; Nestel, 1992). Recent, unpublished data indicate that
the amount of very long chain PUFA derived from alpha-
linolenic acid in blood lipids does not differ between
subjects over 60 y vs subjects under 35 y (Hornstra et al).
Also, no difference has been demonstrated between term
and pre-term infants in their ability to accumulate tissue
EPA from dietary alpha-linolenic acid (Carnielli et al,
1996). In some diseases, for example insulin de®cient
diabetes, chronic alcoholism, and schizophrenia, the
amount of EPA incorporated into tissue lipids from dietary
alpha-linolenic acid may be decreased. In pregnancy-
induced hypertension, the amount of very long chain
PUFA in plasma and tissue phospholipids is increased
(Al et al, 1995).
Does alpha-linolenic acid affect cancer risk?
Data on alpha-linolenic acid and cancer in humans are
scarce (Dolecek, 1992). The results of animal studies are
con¯icting (Johnston, 1995). Increased intake of alpha-
linolenic acid was associated with increased prostate
cancer incidence (Giovannucci et al, 1993; Gann et al,
1994). This ®nding was recently con®rmed in a case-
control study in Finland (Harvei et al, 1997). However,
other studies do not suggest an effect of alpha-linolenic
acid intake on cancer mortality (Kolonel et al, 1988;
Bougnoux et al, 1994). The reason for the observed
relationship between the alpha-linolenic acid intake and
prostate cancer is not clear.
Human experiments with n-3 PUFA
What is the outcome on blood lipids and lipoproteins?
Marine n-3 PUFA in doses of up to 7 g/d (average 3 ± 4 g/d)
lower fasting blood triglycerides by approximately 25%
(Harris, 1997). VLDL lipids are most affected. There is
evidence of a dose-response relation. The post-prandial
triglyceride level is also lowered. LDL cholesterol
increases by 4% in healthy subjects and by 7% in hyper-
triglyceridaemic patients (in addition to an increase in LDL
particle size). HDL cholesterol increases by 3% in healthy
people, but not in hypertriglyceridaemic patients. There are
no indications for a modulating effect of linoleic acid on
the effects of n-3 PUFA on blood lipids.
Dietary alpha-linolenic acid does not affect blood tri-
glycerides, even at high intakes, and it lowers LDL
cholesterol probably only when it replaces saturated fatty
acids.
What is the outcome on neural development?
Both very long chain n-3 and n-6 PUFA are important for
neural development (Innis, 1991; Makrides et al, 1996). An
important issue still is the adequacy of alpha-linolenic acid
in infant food as a precursor for DHA, in particular for pre-
term infants (Salem et al, 1996). In these infants, formulas
enriched with DHA were found to improve visual acuity
and neuro-mental development. These effects disappeared
at somewhat later age (Carlson et al, 1993; Innis et al,
1996), but were of longer duration in other studies (Uauy et
al, 1996). An increased occurrence of sepsis or necrotising
enterocolitis at enteral feeding with supplemented marine
n-3 PUFA cannot be ruled out (Carlson et al, 1996).
Although DHA levels in brain autopsy tissue from babies
fed formulas have been found to be lower than in breast-fed
babies, it is not clear whether supplementation of formulas
with marine n-3 PUFA has bene®cial effects on brain
development.
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Due to the dif®culties in establishing the physiological
consequences of DHA shortage in vivo, the question
whether the addition of DHA alone or in combination
with arachidonic acid to infant formulas confers a physio-
logical bene®t to the infant has not yet been clari®ed. The
same holds true for supplementation with alpha-linolenic
acid at realistic doses to pregnant or lactating mothers in
relation with the health of the new-born (Al et al, 1997). It
is also uncertain to what extent the ratio of linoleic acid to
alpha-linolenic acid and/or the absolute amounts of linoleic
acid and alpha-linolenic acid in the mothers' diet are of
relevance to the health status of the foetus and breast-fed
infant.
What is the outcome on lipid peroxidation?
Oxidised LDL has been implicated in atherosclerosis.
Oxidation of LDL leads to formation of thiobarbituric
acid-reactive substances (TBARS). However, TBARS
re¯ect both the content of PUFA and their oxidizability
in LDL-particles. Moreover, appreciable amounts of
TBARS may be present in foods and absorbed into the
blood stream. Therefore, TBARS (in fact a rather unspe-
ci®c method) should no longer be used as a measure for the
oxidizability of LDL-particles in vivo.
Oxidizability of LDL is measured in vitro and may not
re¯ect oxidation sensitivity of LDL in vivo. Linoleic acid-
enriched LDL particles are oxidised in vitro faster than
LDL particles enriched with saturated or monounsaturated
fatty acids (Reaven et al, 1994). Inconsistent in vitro results
have been published with respect to both plant and marine
n-3 PUFA (Suzukawa et al, 1995; Brude et al, 1997). Both
n-6 and n-3 PUFA, however, should be regarded as sensi-
tive to oxidation in vivo.
Since consumption of n-3 PUFA can be associated with
a higher susceptibility to in vitro oxidizability of LDL, this
should be accompanied by adequate amounts of antioxi-
dants such as a -tocopherol (Muggli, 1994). The established
bene®cial effects of plant and marine n-3 PUFA on other
risk factors for CHD likely outweigh any increased risk
from oxidative changes.
What is the outcome on diabetes?
The effects of dietary n-3 PUFA on CHD risk factors in
diabetics (type II) are not much different from those in non-
diabetics (Axelrod et al, 1994). In some studies marine n-3
PUFA induced a small increase in blood glucose levels in
diabetics (Vessby et al, 1992). Marine n-3 PUFA may
reduce the insulin response (secretion) to glucose, but no
consistent effect of marine n-3 PUFA on insulin sensitivity
has been found. A possible interaction with the n-6 PUFA
in the diet has not been adequately studied. Moderate doses
of marine n-3 PUFA, and also ®sh consumption (Feskens et
al, 1991), may be bene®cial in diabetes, for example by an
effect on triglycerides, but the use of large doses of marine
n-3 PUFA should not be encouraged.
What is the outcome on blood pressure?
Intake of marine n-3 PUFA can reduce blood pressure in
hypertensive but less commonly in normotensive subjects.
A minimum daily amount of 3 g may be needed for a
signi®cant reduction (Appel et al, 1993; Morris et al, 1993).
Typically, 5 ± 6 g n-3 PUFA daily reduced systolic and
diastolic blood pressure by 3.4 and 2.0 mm Hg, respec-
tively, which can be expected to reduce risk for both stroke
and CHD. In epidemiological studies no relation could be
detected between ®sh intake and blood pressure. The
limited data on alpha-linolenic acid show variable effects
(Salonen, 1991; Nestel et al, 1997).
What is the outcome on thrombosis/haemostasis?
Because direct effects on arterial thrombosis can not be
measured, surrogate endpoints have to be used to estimate
effects on thrombotic risk. In endothelial cells (in-vitro
studies) marine n-3 PUFA reduced the levels of mRNA
coding for adhesion molecules and increased prostacyclin
synthesis, whereas effects on nitric oxide release were
inconsistent. Data on effects of marine n-3 PUFA and
alpha-linolenic acid on coagulation and ®brinolysis are
incomplete and inconsistent. Marine n-3 PUFA, but not
alpha-linolenic acid, might reduce the level of circulating
platelet aggregates. Summarising, there are insuf®cient data
on the extent to which the anti-CHD effects of marine n-3
PUFA are mediated by changes in haemostasis (Knapp,
1997).
What is the outcome on arrhythmias?
In animal models alpha-linolenic acid, EPA, DHA, and
other PUFA reduced the susceptibility to ventricular ®bril-
lation and in cardiac myocytes they had antiarrhythmic
activity (Charnock, 1994; Leaf & Kang, 1996). Effects on
ion channels play a role. Epidemiological and clinical
studies also suggest antiarrhythmic effects from the con-
sumption of ®sh and marine n-3 PUFA (Siscovick et al,
1996; Christensen et al, 1997; Singh et al, 1997). The
evidence warrants controlled clinical trials on the effect of
marine n-3 PUFA on ventricular ®brillation (the main cause
of sudden death from acute heart attacks). No human data
are available on the prevention of primary cardiac arrest by
alpha-linolenic acid.
What is the outcome on immune function and
in¯ammation?
Marine n-3 PUFA moderately, but reproducibly, decrease
pain and morning stiffness in rheumatoid arthritis (Kremer,
1996) and may also have bene®cial effects in renal trans-
plantation (fewer complications) and in in¯ammatory
bowel disease. Their effect on immunologic and in¯amma-
tory diseases is probably due to the decrease in (effective)
immune and in¯ammation mediators (eicosanoids and
cytokines) (Endres & Von Schacky, 1996). High dietary
amounts of alpha-linolenic acid may also modestly
decrease eicosanoid and cytokine synthesis, but do not
have a clear effect on immunologic and in¯ammatory
responses. There is no solid evidence that marine n-3
PUFA is effective in asthma and only weak evidence in
psoriasis. There are no epidemiological data for ®sh and
arthritis and there is only one study on alpha-linolenic acid
and arthritis which showed that alpha-linolenic acid was
ineffective. Due to effects of n-3 PUFA on immune and
in¯ammation mediators, an increased intake of EPA might
lead to a suppression of immune and in¯ammation
responses, and consequently, to a decrease in host resis-
tance to infections. However, no adverse effects of marine
n-3 PUFA on infection in humans have been reported.
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Recommendations and conclusions
Are there scienti®c reasons to increase the current intake of
n-3 fatty acids?
There is suf®cient scienti®c evidence to support the view
that marine n-3 PUFA can be bene®cial for health, espe-
cially for those who are at high risk for CHD. The meeting
therefore agreed with the general recommendation to eat
®sh at least once a week. Fatty ®sh is preferable because of
its high content of n-3 PUFA. People who do not eat ®sh
could consider consuming marine n-3 PUFA equivalent to
the amount obtained from fatty ®sh, namely 200 mg EPA
plus DHA daily. This is equivalent to 10 ± 40 g of fatty ®sh
per day. Pregnant women and neonates may require, in
addition to linoleic acid and alpha-linolenic acid, some
intake of very long chain n-3 PUFA to cover the needs for
optimal growth and development.
Should there be separate recommendations for plant and
marine n-3 PUFA?
Separate recommendations for plant and marine n-3 PUFA
may be needed due to their different physiologic effects.
The meeting concluded that there are no scienti®c reasons
to deviate from a recommendation for alpha-linolenic acid
of one energy-%. Because the impact of an advice on intake
of n-3 PUFA could be signi®cant, solid scienti®c under-
pinning through large-scale prospective
studies and randomised controlled clinical trials is required.
In addition, nutritional studies done so far with realistic
amounts of EPA and DHA should be repeated with alpha-
linolenic acid.
Is the use of the n-3/n-6 ratio scienti®cally sensible?
Experience with the polyunsaturated/saturated fatty acid
ratio suggests that the use of a n-3/n-6 ratio will not be
helpful. For instance, one might increase the n-3/n-6 ratio
by lowering of the dietary linoleic acid level, but this does
not have the same effect as increasing the n-3 PUFA level.
The background of the use of the ratio is that the absolute
amounts of n-3 PUFA in the Western diet might be too low
and that the conversion of alpha-linolenic acid to DHA can
be decreased by increasing the dietary amount of linoleic
acid. Although the latter may be true, the absolute dietary
amount of linoleic acid as such is important for CHD and
not the ratio to n-3 PUFA.
Furthermore, alpha-linolenic acid and marine n-3 PUFA
have distinct physiological effects and can not replace each
other. However, the n-3/n-6 ratio is being discussed widely
and is therefore dif®cult to ignore. The meeting concluded
that there should be separate recommendations for alpha-
linolenic acid, marine n-3 PUFA and linoleic acid and that
the n-3/n-6 ratio should not be used.
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